A quick analysis of Celgene Corporation (NASDAQ: CELG) stock history reveals three distinct stages with four stock splits along the way. These stages led to the company becoming what the following chart shows it to be -- one of the …
SUMMIT, N.J. (AP) — Biopharmaceutical company Celgene is buying the remainder of Juno Therapeutics Inc. that it doesn't already own in a deal valued at about $9 billion, which will help it develop medicines for patients with incurable …
At $95.64, the stock has room to fall short-term, even if the positive trends remain in place: “Correction support” comes into play at the $89.70-$91.30 range and the long-term uptrend line comes into play at around $83. Technicians still call …
Biotechnology giant Celgene Corp. said Wednesday that a drug it was testing for a particular type of arthritis failed to reach its goals, but the news seemed to have little effect on the company’s stock price. Instead of falling, Celgene